Detalles de la búsqueda
1.
Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
BMC Cancer
; 23(1): 1098, 2023 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37951905
2.
Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer.
Oncologist
; 26(4): e686-e693, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33321004
3.
Chemoprevention of pancreatic cancer by inhibition of glutathione-S transferase P1.
Invest New Drugs
; 39(6): 1484-1492, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34031785
4.
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
Invest New Drugs
; 39(6): 1568-1576, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34160752
5.
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Invest New Drugs
; 39(1): 152-162, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32564277
6.
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
BMC Cancer
; 21(1): 1111, 2021 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34656107
7.
Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer.
Cancer Sci
; 111(3): 924-931, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31943636
8.
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Oncologist
; 25(6): e909-e919, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32003919
9.
Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).
Cancer Sci
; 109(9): 2980-2985, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30187675
10.
Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
Breast Cancer Res Treat
; 171(2): 501-511, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29915946
11.
Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Br J Cancer
; 116(4): 509-514, 2017 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28081544
12.
Thrombocytosis as a prognostic factor in inflammatory breast cancer.
Breast Cancer Res Treat
; 166(3): 819-832, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28831670
13.
A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors.
Invest New Drugs
; 35(3): 307-314, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28054329
14.
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Oncologist
; 21(1): 21-7, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26659222
15.
Chilblain lupus-like cutaneous reaction associated with systemic lupus erythematosus induced by immune checkpoint inhibitor.
Rheumatology (Oxford)
; 61(1): e13-e14, 2021 12 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34463707
16.
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
Breast Cancer Res Treat
; 152(2): 407-16, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26017070
17.
The role of inflammation in inflammatory breast cancer.
Adv Exp Med Biol
; 816: 53-73, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24818719
18.
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
Cancer Treat Rev
; 125: 102720, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38502995
19.
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
J Clin Oncol
; : JCO2301909, 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38652877
20.
Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.
Breast Cancer Res
; 15(6): R112, 2013 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-24274653